GlassScriptPhysician profile
Hector Nazario
NPI 1437160827
$160,882.12
in general payments reported to CMS, 2019-2025
26 companies · $17K in 2025
The $17K reported for 2025 was more than what 81% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $17K · 2021: $18K · 2022: $19K · 2023: $24K · 2024: $12K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $4,555 · Travel and Lodging: $3,388 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,755.00 |
| Food and Beverage | $4,554.62 |
| Travel and Lodging | $3,387.74 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $82,551.93 | 2019-2025 | Vemlidy |
| Abbvie INC. | $75,041.82 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,723.54 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $374.13 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $353.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $177.43 | 2024-2025 | Iqirvo, Bylvay |
| Novo Nordisk INC | $101.15 | 2024-2025 | Wegovy |
| Siemens Medical Solutions USA, INC. | $73.44 | 2019-2020 | |
| Eisai INC. | $60.47 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $50.42 | 2023 | Terlivaz |
| Intra-Sana Laboratories | $39.37 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Laborie Medical Technologies Corp. | $37.68 | 2024 | Renovarp |
| Merck Sharp & Dohme LLC | $33.29 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $28.10 | 2019 | |
| Alnylam Pharmaceuticals INC. | $27.81 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $27.71 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.57 | 2020-2022 | |
| Vbi Vaccine (Delaware) INC. | $27.36 | 2022 | |
| Shionogi INC | $25.88 | 2019 | |
| Amgen INC. | $20.03 | 2025 | Uplizna |
| Tetraphase Pharmaceuticals, INC. | $17.66 | 2019 | |
| Eton Pharmaceuticals, INC. | $16.82 | 2025 | Galzin, Nitisinone, Betaine Anhydrous |
| Mirum Pharmaceuticals, INC. | $16.45 | 2023 | Livmarli |
| Shire North American Group INC | $14.65 | 2019 | |
| Ethicon US, LLC | $13.46 | 2023 | Neuwave |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Nazario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.